Ligand Pharmaceuticals Incorporated (LGND)
USD 96.67
(-2.76%)
USD 96.67
(-2.76%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 84.32 Million USD | -21.69% |
| 2022 | 140.38 Million USD | 3.17% |
| 2021 | 136.06 Million USD | -7.61% |
| 2020 | 147.26 Million USD | 28.44% |
| 2019 | 114.65 Million USD | 40.87% |
| 2018 | 81.38 Million USD | 20.29% |
| 2017 | 67.66 Million USD | 15.69% |
| 2016 | 58.48 Million USD | 54.89% |
| 2015 | 37.75 Million USD | 8.84% |
| 2014 | 34.69 Million USD | 27.27% |
| 2013 | 27.25 Million USD | 1.34% |
| 2012 | 26.89 Million USD | 6.45% |
| 2011 | 25.26 Million USD | -51.21% |
| 2010 | 51.79 Million USD | -26.35% |
| 2009 | 70.31 Million USD | 33.7% |
| 2008 | 52.59 Million USD | -28.03% |
| 2007 | 73.06 Million USD | -74.55% |
| 2006 | 287.08 Million USD | 75.88% |
| 2005 | 163.23 Million USD | 1.34% |
| 2004 | 161.07 Million USD | 25.16% |
| 2003 | 128.7 Million USD | 28.08% |
| 2002 | 100.48 Million USD | 17.48% |
| 2001 | 85.53 Million USD | -7.41% |
| 2000 | 92.37 Million USD | -1.83% |
| 1999 | 94.1 Million USD | -0.95% |
| 1998 | 95 Million USD | 2.93% |
| 1997 | 92.3 Million USD | 16.69% |
| 1996 | 79.1 Million USD | 48.96% |
| 1995 | 53.1 Million USD | 458.95% |
| 1994 | 9.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 22.97 Million USD | 35.78% |
| 2024 Q1 | 16.92 Million USD | -43.21% |
| 2023 Q1 | 26.05 Million USD | -46.68% |
| 2023 Q2 | 26.68 Million USD | 2.39% |
| 2023 FY | 109.93 Million USD | -21.69% |
| 2023 Q4 | 29.79 Million USD | 4.82% |
| 2023 Q3 | 28.42 Million USD | 6.54% |
| 2022 Q4 | 48.86 Million USD | -4.74% |
| 2022 Q1 | 50.3 Million USD | 5.33% |
| 2022 FY | 140.38 Million USD | 3.17% |
| 2022 Q3 | 51.29 Million USD | 12.68% |
| 2022 Q2 | 45.52 Million USD | -9.49% |
| 2021 Q2 | 8.34 Million USD | -80.27% |
| 2021 Q4 | 47.75 Million USD | 26.73% |
| 2021 FY | 136.06 Million USD | -7.61% |
| 2021 Q1 | 42.28 Million USD | -34.09% |
| 2021 Q3 | 37.68 Million USD | 351.67% |
| 2020 FY | 147.26 Million USD | 28.44% |
| 2020 Q1 | 24.69 Million USD | -29.95% |
| 2020 Q2 | 26.67 Million USD | 8.04% |
| 2020 Q3 | 31.74 Million USD | 19.01% |
| 2020 Q4 | 64.15 Million USD | 102.08% |
| 2019 FY | 114.65 Million USD | 40.87% |
| 2019 Q1 | 25.88 Million USD | 10.19% |
| 2019 Q2 | 26.71 Million USD | 3.21% |
| 2019 Q3 | 26.81 Million USD | 0.4% |
| 2019 Q4 | 35.24 Million USD | 31.42% |
| 2018 Q3 | 20.84 Million USD | 11.25% |
| 2018 Q2 | 18.73 Million USD | 2.22% |
| 2018 Q1 | 18.32 Million USD | -10.05% |
| 2018 Q4 | 23.48 Million USD | 12.69% |
| 2018 FY | 81.38 Million USD | 20.29% |
| 2017 Q2 | 14.07 Million USD | -24.76% |
| 2017 Q3 | 14.49 Million USD | 2.98% |
| 2017 FY | 67.66 Million USD | 15.69% |
| 2017 Q1 | 18.71 Million USD | 18.68% |
| 2017 Q4 | 20.37 Million USD | 40.55% |
| 2016 Q3 | 14.9 Million USD | 6.11% |
| 2016 FY | 58.48 Million USD | 54.89% |
| 2016 Q4 | 15.76 Million USD | 5.74% |
| 2016 Q2 | 14.05 Million USD | 5.23% |
| 2016 Q1 | 13.35 Million USD | 47.42% |
| 2015 Q2 | 11.23 Million USD | 12.85% |
| 2015 Q3 | 7.5 Million USD | -33.16% |
| 2015 FY | 37.75 Million USD | 8.84% |
| 2015 Q4 | 9.05 Million USD | 20.63% |
| 2015 Q1 | 9.95 Million USD | 13.17% |
| 2014 FY | 34.69 Million USD | 27.27% |
| 2014 Q3 | 9.76 Million USD | 23.15% |
| 2014 Q1 | 8.2 Million USD | 20.74% |
| 2014 Q4 | 8.79 Million USD | -9.89% |
| 2014 Q2 | 7.92 Million USD | -3.35% |
| 2013 FY | 27.25 Million USD | 1.34% |
| 2013 Q3 | 7.17 Million USD | 13.31% |
| 2013 Q4 | 6.79 Million USD | -5.24% |
| 2013 Q2 | 6.32 Million USD | -9.17% |
| 2013 Q1 | 6.96 Million USD | 3.08% |
| 2012 Q2 | 6.79 Million USD | 7.44% |
| 2012 FY | 26.89 Million USD | 6.45% |
| 2012 Q1 | 6.32 Million USD | -8.06% |
| 2012 Q4 | 6.75 Million USD | -3.84% |
| 2012 Q3 | 7.02 Million USD | 3.52% |
| 2011 Q4 | 6.87 Million USD | 11.68% |
| 2011 Q1 | 6.16 Million USD | -30.33% |
| 2011 Q2 | 7.09 Million USD | 15.02% |
| 2011 FY | 25.26 Million USD | -51.21% |
| 2011 Q3 | 6.15 Million USD | -13.21% |
| 2010 Q1 | 10.41 Million USD | -63.32% |
| 2010 FY | 51.79 Million USD | -26.35% |
| 2010 Q4 | 8.85 Million USD | -62.3% |
| 2010 Q2 | 9.46 Million USD | -9.07% |
| 2010 Q3 | 23.47 Million USD | 148.01% |
| 2009 Q3 | 12.33 Million USD | 0.28% |
| 2009 Q4 | 28.38 Million USD | 130.07% |
| 2009 Q2 | 12.3 Million USD | -28.81% |
| 2009 Q1 | 17.27 Million USD | 25.41% |
| 2009 FY | 70.31 Million USD | 33.7% |
| 2008 Q3 | 11.6 Million USD | 11.17% |
| 2008 FY | 52.59 Million USD | -28.03% |
| 2008 Q1 | 16.77 Million USD | 21.44% |
| 2008 Q4 | 13.77 Million USD | 18.75% |
| 2008 Q2 | 10.43 Million USD | -37.77% |
| 2007 FY | 73.06 Million USD | -74.55% |
| 2007 Q3 | 14.2 Million USD | -9.97% |
| 2007 Q2 | 15.77 Million USD | -46.12% |
| 2007 Q1 | 29.27 Million USD | 25.32% |
| 2007 Q4 | 13.81 Million USD | -2.75% |
| 2006 Q4 | 23.36 Million USD | -49.18% |
| 2006 FY | 287.08 Million USD | 75.88% |
| 2006 Q3 | 45.97 Million USD | -6.51% |
| 2006 Q1 | 178.31 Million USD | 330.31% |
| 2006 Q2 | 49.17 Million USD | -72.42% |
| 2005 Q2 | 41.63 Million USD | -0.12% |
| 2005 FY | 163.23 Million USD | 1.34% |
| 2005 Q3 | 36.29 Million USD | -12.84% |
| 2005 Q4 | 41.43 Million USD | 14.18% |
| 2005 Q1 | 41.69 Million USD | 7.3% |
| 2004 Q4 | 38.85 Million USD | -8.3% |
| 2004 Q3 | 42.37 Million USD | 1.37% |
| 2004 Q2 | 41.79 Million USD | 9.84% |
| 2004 Q1 | 38.05 Million USD | -0.62% |
| 2004 FY | 161.07 Million USD | 25.16% |
| 2003 Q4 | 38.29 Million USD | 23.87% |
| 2003 Q1 | 29.06 Million USD | 6.29% |
| 2003 FY | 128.7 Million USD | 28.08% |
| 2003 Q2 | 30.43 Million USD | 4.69% |
| 2003 Q3 | 30.91 Million USD | 1.58% |
| 2002 Q2 | 23.96 Million USD | 5.21% |
| 2002 Q4 | 27.34 Million USD | 3.56% |
| 2002 FY | 100.48 Million USD | 17.48% |
| 2002 Q1 | 22.77 Million USD | 9.46% |
| 2002 Q3 | 26.4 Million USD | 10.21% |
| 2001 Q1 | 23.49 Million USD | 52.78% |
| 2001 Q4 | 20.8 Million USD | 3.56% |
| 2001 Q3 | 20.08 Million USD | -12.71% |
| 2001 FY | 85.53 Million USD | -7.41% |
| 2001 Q2 | 23.01 Million USD | -2.06% |
| 2000 Q2 | 26.36 Million USD | 6.68% |
| 2000 Q4 | 15.38 Million USD | -40.65% |
| 2000 Q3 | 25.91 Million USD | -1.71% |
| 2000 FY | 92.37 Million USD | -1.83% |
| 2000 Q1 | 24.71 Million USD | 32.87% |
| 1999 Q2 | 26.2 Million USD | 11.49% |
| 1999 Q3 | 25.8 Million USD | -1.53% |
| 1999 FY | 94.1 Million USD | -0.95% |
| 1999 Q1 | 23.5 Million USD | -22.95% |
| 1999 Q4 | 18.6 Million USD | -27.91% |
| 1998 Q1 | 19.5 Million USD | -26.14% |
| 1998 FY | 95 Million USD | 2.93% |
| 1998 Q4 | 30.5 Million USD | 34.96% |
| 1998 Q3 | 22.6 Million USD | 0.89% |
| 1998 Q2 | 22.4 Million USD | 14.87% |
| 1997 Q3 | 23 Million USD | 6.48% |
| 1997 Q4 | 26.4 Million USD | 14.78% |
| 1997 FY | 92.3 Million USD | 16.69% |
| 1997 Q1 | 21.2 Million USD | -6.61% |
| 1997 Q2 | 21.6 Million USD | 1.89% |
| 1996 FY | 79.1 Million USD | 48.96% |
| 1996 Q1 | 16 Million USD | -3.03% |
| 1996 Q2 | 18.6 Million USD | 16.25% |
| 1996 Q3 | 21.7 Million USD | 16.67% |
| 1996 Q4 | 22.7 Million USD | 4.61% |
| 1995 FY | 53.1 Million USD | 458.95% |
| 1995 Q1 | 9.4 Million USD | 176.47% |
| 1995 Q4 | 16.5 Million USD | 8.55% |
| 1995 Q3 | 15.2 Million USD | 0.0% |
| 1995 Q2 | - USD | -100.0% |
| 1994 Q2 | 2 Million USD | 0.0% |
| 1994 FY | 9.5 Million USD | 0.0% |
| 1994 Q3 | 2.1 Million USD | 5.0% |
| 1994 Q4 | 3.4 Million USD | 61.9% |
| 1994 Q1 | 2 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | 201.11 Million USD | 58.072% |
| Jaguar Health, Inc. | 42.01 Million USD | -100.697% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 50.186% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -48.563% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 95.316% |
| ContextLogic Inc. | 387 Million USD | 78.211% |
| MiMedx Group, Inc. | 229.72 Million USD | 63.294% |
| MEI Pharma, Inc. | 34.78 Million USD | -142.412% |
| AlloVir, Inc. | 180.93 Million USD | 53.395% |
| Novavax, Inc. | 779.12 Million USD | 89.177% |
| Aptorum Group Limited | 10.56 Thousand USD | -797959.814% |
| Ardelyx, Inc. | 169.93 Million USD | 50.38% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 81.082% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -2964.525% |
| Vaxcyte, Inc. | 468.04 Million USD | 81.984% |
| Precigen, Inc. | 84.18 Million USD | -0.169% |
| Pharming Group N.V. | 225.49 Million USD | 62.605% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 49.756% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -16.202% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 35.267% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 65.605% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -334.24% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -246.914% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -246.914% |
| Bicycle Therapeutics plc | 216.92 Million USD | 61.128% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 63.126% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -173.253% |
| Acelyrin, Inc. | 422.06 Million USD | 80.021% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -122.67% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -127.506% |
| Senti Biosciences, Inc. | 94.7 Million USD | 10.962% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 31.752% |
| AbCellera Biologics Inc. | 275.23 Million USD | 69.363% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -186.141% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 50.947% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 36.204% |
| Chimerix, Inc. | 93.38 Million USD | 9.708% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -147.39% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -383.033% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -506.22% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -66.341% |
| Elevation Oncology, Inc. | 45.44 Million USD | -85.55% |
| Alkermes plc | 996.24 Million USD | 91.536% |
| Fortress Biotech, Inc. | 200.19 Million USD | 57.88% |
| Fortress Biotech, Inc. | 200.19 Million USD | 57.88% |
| Agenus Inc. | 78.18 Million USD | -7.853% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -157.506% |
| Dyadic International, Inc. | 9.15 Million USD | -821.291% |
| ImmuCell Corporation | 9.61 Million USD | -776.779% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -278.929% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 46.568% |
| Lantern Pharma Inc. | 17.87 Million USD | -371.669% |
| Immix Biopharma, Inc. | 16.14 Million USD | -422.411% |
| Incyte Corporation | 1.19 Billion USD | 92.917% |
| IO Biotech, Inc. | 91.44 Million USD | 7.786% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -4.023% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -1152.58% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -58.722% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -174.034% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -897.787% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 0.464% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 77.839% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 79.105% |
| NextCure, Inc. | 67.63 Million USD | -24.67% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -184.817% |
| Onconetix, Inc. | 34.9 Million USD | -141.562% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -561.564% |
| Opthea Limited | 191.96 Million USD | 56.074% |
| PDS Biotechnology Corporation | 43.04 Million USD | -95.894% |
| PureTech Health plc | 144.59 Million USD | 41.684% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -2.588% |
| Seer, Inc. | 110.49 Million USD | 23.683% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -653870.839% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -157.75% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -2039.066% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -184.088% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 53.49% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 49.938% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 47.228% |
| ChromaDex Corporation | 56.37 Million USD | -49.565% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -345.47% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 43.985% |
| CRISPR Therapeutics AG | 463.49 Million USD | 81.807% |
| Precision BioSciences, Inc. | 92.46 Million USD | 8.804% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 66.808% |
| Innoviva, Inc. | 132.15 Million USD | 36.193% |
| Summit Therapeutics Inc. | 87.68 Million USD | 3.835% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -19.448% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 9.794% |
| ESSA Pharma Inc. | 32.13 Million USD | -162.41% |
| GlycoMimetics, Inc. | 39.28 Million USD | -114.643% |
| GT Biopharma, Inc. | 13.57 Million USD | -521.118% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 61.642% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 67.496% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -55.923% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -748.521% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 67.525% |
| Aptose Biosciences Inc. | 52.35 Million USD | -61.057% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -485.155% |
| Soligenix, Inc. | 7.79 Million USD | -981.723% |
| Century Therapeutics, Inc. | 56.07 Million USD | -50.386% |
| Kura Oncology, Inc. | 165.8 Million USD | 49.143% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 26.36% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -913.619% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -3297.875% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 21.704% |
| Autolus Therapeutics plc | 196.72 Million USD | 57.137% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 0.395% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 27.591% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -335.036% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 73.793% |
| GRI Bio, Inc. | 11.33 Million USD | -644.245% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -1095.104% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 35.726% |
| IGM Biosciences, Inc. | 265.59 Million USD | 68.251% |
| INmune Bio, Inc. | 29.89 Million USD | -182.054% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 51.132% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -109.164% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -427.699% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -435.671% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -35.79% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 21.576% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 69.414% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 72.028% |
| Verastem, Inc. | 92.08 Million USD | 8.428% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -370.054% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 54.598% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 30.545% |
| Histogen Inc. | 14.27 Million USD | -490.828% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -425.438% |
| Surrozen, Inc. | 18.55 Million USD | -354.571% |
| Organovo Holdings, Inc. | 14.91 Million USD | -465.357% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -1556.564% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -41.308% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -228.783% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -79.388% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -1004.739% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 52.664% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -74.049% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 65.583% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -448.743% |
| Apollomics, Inc. | 54.14 Million USD | -55.75% |
| Amarin Corporation plc | 272.35 Million USD | 69.04% |
| Mesoblast Limited | 5.9 Million USD | -1328.719% |
| Turnstone Biologics Corp. | 78.33 Million USD | -7.64% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 65.459% |
| Synaptogenix, Inc. | 8.31 Million USD | -914.247% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -478.109% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 66.678% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -152.994% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -854.827% |
| Exelixis, Inc. | 1.58 Billion USD | 94.686% |
| Better Therapeutics, Inc. | 38.26 Million USD | -120.383% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 63.662% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 90.14% |
| NLS Pharmaceutics AG | 11.8 Million USD | -614.174% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -948.545% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -181.142% |
| Gritstone bio, Inc. | 148.37 Million USD | 43.169% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -22.454% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -415.415% |
| Avid Bioservices, Inc. | 25.99 Million USD | -224.369% |
| Insmed Incorporated | 949.26 Million USD | 91.117% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -437.439% |
| MediWound Ltd. | 18.86 Million USD | -346.91% |
| OmniAb, Inc. | 83.89 Million USD | -0.51% |
| Alector, Inc. | 248.8 Million USD | 66.108% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 64.012% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -61.381% |
| Zai Lab Limited | 547.47 Million USD | 84.598% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 78.848% |
| Aura Biosciences, Inc. | 84.99 Million USD | 0.786% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 65.88% |
| Immunic, Inc. | 99.22 Million USD | 15.017% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 46.971% |
| Veracyte, Inc. | 357.93 Million USD | 76.442% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.065% |
| FibroGen, Inc. | 398.11 Million USD | 78.819% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -493.406% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -1124.211% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -1083.359% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 97.41% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -225.911% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 73.361% |
| TG Therapeutics, Inc. | 198.47 Million USD | 57.515% |
| Galecto, Inc. | 35.62 Million USD | -136.683% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -107.238% |
| Fortrea Holdings Inc. | 457.3 Million USD | 81.561% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -55.354% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -191.997% |
| XBiotech Inc. | 37.51 Million USD | -124.801% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -22.454% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -308.364% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 40.643% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 14.89% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 23.838% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 91.2% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -192.331% |
| Vaxxinity, Inc. | 56.05 Million USD | -50.44% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 80.419% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -277.989% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 23.942% |
| NexImmune, Inc. | 28.16 Million USD | -199.363% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -1424.567% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -371.275% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 97.005% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -231.211% |
| Scopus BioPharma Inc. | 11.71 Million USD | -619.794% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 33.636% |
| Ainos, Inc. | 12.95 Million USD | -551.009% |
| Pluri Inc. | 22.48 Million USD | -275.102% |
| Prothena Corporation plc | 282.4 Million USD | 70.141% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 57.843% |
| Celularity Inc. | 215.05 Million USD | 60.791% |
| Rallybio Corporation | 78.93 Million USD | -6.83% |
| Cue Biopharma, Inc. | 19.54 Million USD | -331.496% |
| MeiraGTx Holdings plc | 151.07 Million USD | 44.186% |
| Omeros Corporation | 94.75 Million USD | 11.006% |
| Humacyte, Inc. | 23.49 Million USD | -258.867% |
| Immunocore Holdings plc | 308.04 Million USD | 72.626% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -2387.404% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 2.926% |
| Blueprint Medicines Corporation | 722.86 Million USD | 88.335% |
| CalciMedica, Inc. | 21.81 Million USD | -286.501% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -12.943% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 47.475% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 50.773% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 71.41% |
| Pulmatrix, Inc. | 22.03 Million USD | -282.625% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -143.884% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 5.112% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 84.712% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -16.226% |
| Cytokinetics, Incorporated | 173.61 Million USD | 51.43% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -144.99% |
| Nutriband Inc. | 5.73 Million USD | -1370.571% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -93.344% |
| Vor Biopharma Inc. | 126.03 Million USD | 33.096% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 92.909% |
| Evogene Ltd. | 27.79 Million USD | -203.429% |
| ProKidney Corp. | 151.52 Million USD | 44.349% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -13.681% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -996.208% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 86.272% |
| CorMedix Inc. | 48.95 Million USD | -72.236% |
| BioLineRx Ltd. | 50.8 Million USD | -65.984% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 44.046% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -121.483% |
| Atai Life Sciences N.V. | 125.78 Million USD | 32.963% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -3.287% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -3.579% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 66.612% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -157.553% |
| MediciNova, Inc. | 10.9 Million USD | -673.587% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 34.542% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -1061.55% |
| GeoVax Labs, Inc. | 6.02 Million USD | -1300.209% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 82.298% |
| Biomea Fusion, Inc. | 126.13 Million USD | 33.149% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 93.572% |
| Mereo BioPharma Group plc | 35.84 Million USD | -135.263% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 55.872% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 63.33% |
| Absci Corporation | 73.66 Million USD | -14.467% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -205.717% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 36.879% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 65.179% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 67.822% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 59.459% |
| Allakos Inc. | 196.05 Million USD | 56.99% |
| Imunon, Inc. | 20.31 Million USD | -315.171% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 25.686% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 77.124% |
| BioAtla, Inc. | 129.68 Million USD | 34.98% |
| NLS Pharmaceutics AG | 11.8 Million USD | -614.174% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -432.241% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 0.701% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -101.933% |
| XOMA Corporation | 46.46 Million USD | -81.484% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 24.15% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 40.811% |
| aTyr Pharma, Inc. | 12.97 Million USD | -549.688% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 18.651% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 51.222% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 66.902% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -125.414% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -925.227% |
| Akari Therapeutics, Plc | 16.8 Million USD | -401.743% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -3608.184% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 71.828% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -1153.179% |
| UroGen Pharma Ltd. | 138.88 Million USD | 39.287% |
| Sutro Biopharma, Inc. | 243 Million USD | 65.3% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -1059.139% |
| Orgenesis Inc. | 45.75 Million USD | -84.284% |
| Entera Bio Ltd. | 8.86 Million USD | -851.727% |
| GH Research PLC | 41.22 Million USD | -104.558% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -228.003% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -1.529% |
| Xencor, Inc. | 306.97 Million USD | 72.531% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -1609.156% |
| Replimune Group, Inc. | 234.77 Million USD | 64.083% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -311.535% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 56.035% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -1153.179% |
| Portage Biotech Inc. | 18.19 Million USD | -363.339% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -1061.55% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 19.663% |
| OncoCyte Corporation | 25.63 Million USD | -228.911% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -1283.34% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -635.992% |
| Purple Biotech Ltd. | -22.46 Million USD | 475.319% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -411.669% |
| scPharmaceuticals Inc. | 65.17 Million USD | -29.373% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -897.582% |
| HilleVax, Inc. | 133.34 Million USD | 36.763% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -719.864% |
| Tharimmune, Inc. | 9.45 Million USD | -791.814% |
| Genprex, Inc. | 31.06 Million USD | -171.479% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 55.034% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -168.741% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -10922.614% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -1448.086% |
| OKYO Pharma Limited | 8243.57 USD | -1022794.207% |
| Savara Inc. | 15.74 Million USD | -435.554% |
| Curis, Inc. | 58.35 Million USD | -44.5% |
| Daré Bioscience, Inc. | 33.6 Million USD | -150.891% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -1555.831% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -1030.184% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -212.053% |
| BeiGene, Ltd. | 3.28 Billion USD | 97.434% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -322.898% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 83.094% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 45.121% |
| Erasca, Inc. | 141.52 Million USD | 40.418% |
| bluebird bio, Inc. | 240.23 Million USD | 64.899% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -1762.679% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 95.171% |
| DBV Technologies S.A. | 92.16 Million USD | 8.504% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -1762.679% |
| Moderna, Inc. | 6.39 Billion USD | 98.681% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -97.9% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -486.962% |
| Molecular Templates, Inc. | 63.09 Million USD | -33.653% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -26.419% |
| Travere Therapeutics, Inc. | 472 Million USD | 82.135% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 41.161% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -35.825% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -94.23% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 59.485% |
| MacroGenics, Inc. | 217.21 Million USD | 61.18% |
| RenovoRx, Inc. | 11.39 Million USD | -639.935% |
| Adicet Bio, Inc. | 152.03 Million USD | 44.538% |
| Prime Medicine, Inc. | 186.63 Million USD | 54.82% |
| Aditxt, Inc. | 25.95 Million USD | -224.935% |
| Adagene Inc. | 41.83 Million USD | -101.578% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -1053.514% |
| Quantum-Si incorporated | 111.65 Million USD | 24.482% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 50.932% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -478.436% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -135.394% |
| SciSparc Ltd. | 9.01 Million USD | -835.778% |
| Vericel Corporation | 142.04 Million USD | 40.634% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -874.082% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -265.215% |
| Generation Bio Co. | 144.46 Million USD | 41.632% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -1.557% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 2.472% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 71.486% |
| Invivyd, Inc. | 205.75 Million USD | 59.018% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -16.857% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -799.109% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -12.051% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -719.704% |
| 2seventy bio, Inc. | 289.88 Million USD | 70.912% |
| ADMA Biologics, Inc. | 66.58 Million USD | -26.638% |
| Clene Inc. | 41.07 Million USD | -105.3% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -558.368% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -53.885% |
| GeoVax Labs, Inc. | 6.02 Million USD | -1300.209% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 76.048% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -129.563% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -150.009% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 18.687% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -158.747% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 50.479% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 89.016% |
| Evaxion Biotech A/S | 22.27 Million USD | -278.639% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 37.789% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 64.1% |
| Trevena, Inc. | 38.41 Million USD | -119.517% |
| Surrozen, Inc. | 18.55 Million USD | -354.571% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -5.476% |
| Cingulate Inc. | 22.75 Million USD | -270.501% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 1225.507% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -88.781% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -924.09% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 17.78% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 88.818% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -35.843% |
| Clearmind Medicine Inc. | 8.74 Million USD | -864.645% |
| Kronos Bio, Inc. | 128.11 Million USD | 34.183% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -0.299% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -2774.989% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 16.369% |
| Statera Biopharma, Inc. | 28.82 Million USD | -192.489% |
| ImmunityBio, Inc. | 362.87 Million USD | 76.762% |
| Korro Bio, Inc. | 84.53 Million USD | 0.25% |
| Kineta, Inc. | 21.15 Million USD | -298.577% |
| BioVie Inc. | 31.95 Million USD | -163.92% |
| Codexis, Inc. | 66.51 Million USD | -26.767% |
| Celularity Inc. | 215.05 Million USD | 60.791% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 62.791% |
| Celcuity Inc. | 66.23 Million USD | -27.318% |
| Virax Biolabs Group Limited | 6.54 Million USD | -1187.952% |
| Cibus, Inc. | 320.3 Million USD | 73.674% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -96.1% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -149.152% |
| IN8bio, Inc. | 30.33 Million USD | -177.954% |
| Kodiak Sciences Inc. | 277.32 Million USD | 69.594% |
| Annexon, Inc. | 143.72 Million USD | 41.33% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 33.911% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -268.078% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -13075.469% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 89.184% |
| Eyenovia, Inc. | 25.4 Million USD | -231.896% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 39.905% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -1416.055% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -6.559% |
| Arcellx, Inc. | 200.19 Million USD | 57.88% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -83.71% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 61.036% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -746.872% |
| Moolec Science SA | 52.75 Million USD | -59.852% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -37.922% |
| Geron Corporation | 70.44 Million USD | -19.707% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -81.184% |
| Royalty Pharma plc | 862.4 Million USD | 90.222% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 10.363% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -803.99% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -272.64% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 59.423% |
| Humacyte, Inc. | 23.49 Million USD | -258.867% |
| Structure Therapeutics Inc. | 102.77 Million USD | 17.954% |
| 89bio, Inc. | 151.2 Million USD | 44.232% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -5.23% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -479.938% |
| Genelux Corporation | 24.33 Million USD | -246.509% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -148.572% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 51.221% |
| Notable Labs, Ltd. | 14.77 Million USD | -470.907% |
| Liquidia Corporation | 87.98 Million USD | 4.161% |
| Mustang Bio, Inc. | 48.5 Million USD | -73.858% |
| Immunovant, Inc. | 282.7 Million USD | 70.173% |
| Quantum-Si incorporated | 111.65 Million USD | 24.482% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -274.037% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -296.497% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 17.34% |
| Acasti Pharma Inc. | 11.3 Million USD | -646.155% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -267.884% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -427.699% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -81.176% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -7332.089% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -430.801% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -189.203% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -103.757% |
| PepGen Inc. | 84.76 Million USD | 0.523% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -184.577% |
| United Therapeutics Corporation | 885.1 Million USD | 90.473% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -268.271% |
| Solid Biosciences Inc. | 104.31 Million USD | 19.165% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -157.667% |
| Immuneering Corporation | 58.41 Million USD | -44.357% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -1556.564% |
| Silo Pharma, Inc. | 3.92 Million USD | -2050.079% |
| Belite Bio, Inc | 31.66 Million USD | -166.272% |
| XOMA Corporation | 46.46 Million USD | -81.484% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -24.83% |
| Bionomics Limited | 17.89 Billion USD | 99.529% |
| Apogee Therapeutics, Inc. | 93 Million USD | 9.333% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 336.331% |
| uniQure N.V. | 285.08 Million USD | 70.422% |
| Cassava Sciences, Inc. | 105.95 Million USD | 20.418% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -1053.514% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 56.581% |
| Forte Biosciences, Inc. | 32.47 Million USD | -159.639% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -914.869% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -186.862% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -1416.055% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -493.406% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -848.622% |
| Altimmune, Inc. | 30.55 Million USD | -175.962% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 80.282% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 336.331% |
| Compugen Ltd. | 43.97 Million USD | -91.77% |
| Peak Bio, Inc. | 1249.13 USD | -6750438.375% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -13.766% |
| Benitec Biopharma Inc. | 22.38 Million USD | -276.745% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 65.326% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -195.424% |
| Zura Bio Limited | 62.63 Million USD | -34.62% |
| PolyPid Ltd. | 21.04 Million USD | -300.679% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -418.082% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -195.424% |
| Instil Bio, Inc. | 85.78 Million USD | 1.704% |
| argenx SE | 1.53 Billion USD | 94.501% |
| Immunome, Inc. | 122.82 Million USD | 31.344% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -73.959% |
| Verona Pharma plc | 67.15 Million USD | -25.572% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -225.76% |
| Shattuck Labs, Inc. | 93.61 Million USD | 9.925% |
| CervoMed Inc. | 14.95 Million USD | -463.741% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -19.264% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -886.926% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -65.339% |
| Moolec Science SA | 52.75 Million USD | -59.852% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -412.65% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 36.386% |
| AnaptysBio, Inc. | 181.56 Million USD | 53.558% |
| Design Therapeutics, Inc. | 78.19 Million USD | -7.844% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 3.123% |
| NeurAxis, Inc. | 8.82 Million USD | -855.913% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -570.028% |
| Lumos Pharma, Inc. | 38.66 Million USD | -118.086% |
| Achilles Therapeutics plc | 75.25 Million USD | -12.05% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -225.76% |
| 180 Life Sciences Corp. | 13.47 Million USD | -525.658% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -218.171% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -2774.989% |
| Nutriband Inc. | 5.73 Million USD | -1370.571% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 23.882% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -51.516% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -65.732% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -27.571% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -55.799% |
| Palisade Bio, Inc. | 13.32 Million USD | -533.056% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -85.697% |
| Beam Therapeutics Inc. | 554.19 Million USD | 84.785% |
| Neurogene Inc. | 55.58 Million USD | -51.706% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 66.066% |
| AEON Biopharma, Inc. | 48.42 Million USD | -74.117% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 12.808% |
| Sesen Bio, Inc. | 78.38 Million USD | -7.581% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -0.951% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -569.927% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 81.303% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 4.058% |
| Athira Pharma, Inc. | 125.46 Million USD | 32.792% |
| Vaccinex, Inc. | 23.45 Million USD | -259.51% |
| HCW Biologics Inc. | 21.02 Million USD | -301.013% |
| XOMA Corporation | 46.46 Million USD | -81.484% |
| Nektar Therapeutics | 190.9 Million USD | 55.829% |
| Arvinas, Inc. | 480 Million USD | 82.433% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -3608.184% |
| Merus N.V. | 200.49 Million USD | 57.942% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 18.414% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -143.567% |
| Rezolute, Inc. | 70.38 Million USD | -19.799% |
| Clene Inc. | 41.07 Million USD | -105.3% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -414.84% |
| BeyondSpring Inc. | 24.86 Million USD | -239.123% |
| Synlogic, Inc. | 58.53 Million USD | -44.063% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -371.289% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -1777.182% |
| Peak Bio, Inc. | 1249.13 USD | -6750438.375% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -39.501% |
| Krystal Biotech, Inc. | 160.42 Million USD | 47.438% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 68.842% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 75.772% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -3809.754% |
| MannKind Corporation | 125.59 Million USD | 32.862% |
| Ikena Oncology, Inc. | 84.57 Million USD | 0.3% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -774.085% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 5.891% |
| Gossamer Bio, Inc. | 183.75 Million USD | 54.112% |
| CohBar, Inc. | 12.38 Million USD | -580.667% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -66.239% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -205.717% |
| Legend Biotech Corporation | 583.14 Million USD | 85.54% |
| Mural Oncology plc | 192.07 Million USD | 56.098% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -25.58% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -422.277% |
| Disc Medicine, Inc. | 91.12 Million USD | 7.464% |
| Champions Oncology, Inc. | 28.11 Million USD | -199.975% |
| REGENXBIO Inc. | 321.15 Million USD | 73.744% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -1472.828% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -51.236% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -116.431% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 26.263% |
| Vaxart, Inc. | 90.72 Million USD | 7.058% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -889.706% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -97.044% |
| Cellectis S.A. | 97.32 Million USD | 13.355% |
| Longeveron Inc. | 21.25 Million USD | -296.814% |
| Repare Therapeutics Inc. | 167.35 Million USD | 49.615% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 93.804% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -11.472% |
| Revolution Medicines, Inc. | 498.76 Million USD | 83.094% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -1167.634% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -91.844% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -13.049% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -21.093% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -662.414% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 98.234% |
| Denali Therapeutics Inc. | 527.23 Million USD | 84.006% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -874.082% |
| Veru Inc. | 101.34 Million USD | 16.799% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -260.247% |
| Cingulate Inc. | 22.75 Million USD | -270.501% |
| Passage Bio, Inc. | 108.38 Million USD | 22.203% |
| Context Therapeutics Inc. | 25.07 Million USD | -236.315% |
| Exicure, Inc. | 14.07 Million USD | -499.055% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 59.079% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -94.737% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -818.822% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 66.603% |
| Nuvalent, Inc. | 149.49 Million USD | 43.594% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -945.296% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 18.646% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -293.133% |
| OmniAb, Inc. | 83.89 Million USD | -0.51% |
| Anew Medical, Inc. | 1.3 Million USD | -6382.191% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -157.365% |
| Lipocine Inc. | 15.08 Million USD | -459.166% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -23.076% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -10.73% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -109.164% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 26.575% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -276.711% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 87.304% |
| Ocugen, Inc. | 71.56 Million USD | -17.824% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 10.167% |
| Q32 Bio Inc. | 92.68 Million USD | 9.017% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -298.238% |
| Alumis Inc. Common Stock | 158.17 Million USD | 46.69% |
| Equillium, Inc. | 50.6 Million USD | -66.626% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -35.12% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -506.398% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -346.979% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -79.598% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 22.259% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -580.423% |
| Dominari Holdings Inc. | 23.83 Million USD | -253.778% |
| Edesa Biotech, Inc. | 9.22 Million USD | -814.293% |
| vTv Therapeutics Inc. | 11.9 Million USD | -608.18% |
| Bio-Techne Corporation | 563.03 Million USD | 85.024% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 79.373% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 68.625% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 36.253% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -485.129% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 48.488% |
| Nkarta, Inc. | 131.65 Million USD | 35.949% |
| BioCardia, Inc. | 12.12 Million USD | -595.677% |
| Iterum Therapeutics plc | 47.46 Million USD | -77.642% |